These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34131661)

  • 1. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
    Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenco AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz N; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings C; Rothenberg ME; Pöhlmann S; Whelan SP; O'Donoghue AJ; Craik CS; Janetka JW
    bioRxiv; 2021 May; ():. PubMed ID: 34131661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
    Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
    Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
    J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19.
    Boon ACM; L Bricker T; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
    Shirato K; Kawase M; Matsuyama S
    J Virol; 2013 Dec; 87(23):12552-61. PubMed ID: 24027332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
    Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
    Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
    Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    bioRxiv; 2021 Aug; ():. PubMed ID: 34100014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
    Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
    Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.
    Chen Y; Huang WC; Yang CS; Cheng FJ; Chiu YF; Chen HF; Huynh TK; Huang CF; Chen CH; Wang HC; Hung MC
    Am J Cancer Res; 2021; 11(3):827-836. PubMed ID: 33791156
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Salleh MZ; Deris ZZ
    Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties.
    Hempel T; Elez K; Krüger N; Raich L; Shrimp JH; Danov O; Jonigk D; Braun A; Shen M; Hall MD; Pöhlmann S; Hoffmann M; Noé F
    Chem Sci; 2021 Oct; 12(38):12600-12609. PubMed ID: 34703545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
    Zhu H; Du W; Song M; Liu Q; Herrmann A; Huang Q
    Comput Struct Biotechnol J; 2021; 19():467-476. PubMed ID: 33505639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.
    Yamamoto M; Matsuyama S; Li X; Takeda M; Kawaguchi Y; Inoue JI; Matsuda Z
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6532-6539. PubMed ID: 27550352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
    Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
    bioRxiv; 2020 Aug; ():. PubMed ID: 32596694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.
    Azouz NP; Klingler AM; Callahan V; Akhrymuk IV; Elez K; Raich L; Henry BM; Benoit JL; Benoit SW; Noé F; Kehn-Hall K; Rothenberg ME
    Pathog Immun; 2021; 6(1):55-74. PubMed ID: 33969249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, virtual screening and molecular dynamic analysis of novel TMPRSS2 inhibitors from natural compound database as potential entry-blocking agents in SARS-CoV-2 therapy.
    Manandhar S; Pai KSR; Krishnamurthy PT; Kiran AVVVR; Kumari GK
    Struct Chem; 2022; 33(5):1609-1617. PubMed ID: 35754942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat.
    Hempel T; Raich L; Olsson S; Azouz NP; Klingler AM; Hoffmann M; Pöhlmann S; Rothenberg ME; Noé F
    Chem Sci; 2021 Jan; 12(3):983-992. PubMed ID: 35382133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.